GENE ONLINE|News &
Opinion
Blog

2020-11-28| Asia-PacificCOVID-19

Russian Vaccine Makers Nudge AstraZeneca to Combine COVID-19 Vaccine, AZD1222 with Sputnik V

by Sangeeta Chakraborty
Share To

Russia has claimed that its COVID-19 vaccine, Sputnik V is 92% effective at protecting people from COVID-19, based on an interim analysis of trial results. Sputnik V is the world’s first registered vaccine based on a well-studied human adenoviral vector-based platform. The ongoing Sputnik V post-registration clinical trial in Russia involves 40,000 volunteers.

On November 26th, developers of Sputnik V urged AstraZeneca to combine its vaccine, AZD1222 (ChAdOx1 nCoV-19), with the Russian one to improve efficacy. Earlier this week, AstraZeneca and its partner, Oxford University, announced that their vaccine had an efficacy of 90%, but it soon emerged that the promising results are due to erroneous dosing. The vaccine had only reached 62% efficacy when the correct two full doses were administered but rose to a staggering 90% when volunteers were accidentally given a half dose followed by a full one. The company averaged that and said its vaccine appeared to have a 70% efficacy.

Oxford University stated that some of the vials did not have the correct vaccine concentration, so some participants got a half dose. Since then, scientists have raised concerns over the AZ vaccine as it became apparent that a manufacturing error had led to such a high efficacy.

As per reports from Bloomberg News, Pascal Soriat, CEO of AstraZeneca, was quoted as saying that the company is likely to launch a fresh global study to assess the lower dosage of the vaccine that yielded better results than the full dosage. Soriot said he did not expect the additional trial to delay British and European regulatory approvals.

 

Proposal for Combining the Two Vaccines

With over 2 million infections, Russia has the fourth most COVID-19 cases globally, behind the US, India, and Brazil.

“If they go for a new clinical trial, we suggest trying a regimen of combining the AZ shot with the #SputnikV human adenoviral vector shot to boost efficacy,” Sputnik makers tweeted yesterday. “Combining vaccines may prove important for revaccinations.”

AstraZeneca’s vaccine is in a race against both Pfizer’s and Moderna’s mRNA based vaccines, whose shots have reported efficacy of around 95%. However, the AstraZeneca shot could well be one of the best options for many developing countries because of its lower price, easier distribution owing to its stability at fridge temperatures, and faster scale-up than its rivals.

When asked about these doubts in efficacy, the British government’s Chief Scientific Adviser Patrick Vallance said the main point about the AstraZeneca vaccine was that it worked.

“The headline result is the vaccine works, and that’s very exciting,” Vallance said during a news briefing with British Prime Minister Boris Johnson.

By Sangeeta Chakraborty, Ph.D.

Editor: Rajaneesh K. Gopinath, Ph.D.

Related Article: Cheaper and Fridge-Stable AstraZeneca Vaccine is 90% Effective in Preventing COVID-19

References
  1. https://www.reuters.com/article/health-coronavirus-astrazeneca-sputnik/russias-sputnik-v-developers-call-on-astrazeneca-to-try-combining-vaccines-idUSL1N2IC1GN
  2. https://www.reuters.com/article/us-health-coronavirus-astrazeneca-idUSKBN28620H

 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
CDC Warns Of “Tripledemic” Winter Amid Rising Flu And RSV Cases
2022-11-14
Sanofi, GSK Secure European COVID-19 Booster Approval, AstraZeneca Withdraws U.S. Application
2022-11-10
The First Approved RSV Vaccine Worldwide Belongs to AstraZeneca and Sanofi
2022-11-06
LATEST
Relmada Blames ‘Implausible Placebo Results’ on Depression Drug’s Failure Again
2022-12-07
Using Sound Waves to Sort Blood-Based Nanoparticles
2022-12-07
Summit Bets $5 Billion On Akeso’s Bispecific Antibody
2022-12-07
Pharming announces publication of data from Phase 3 Study of leniolisib in patients with APDS in ASH's Blood
2022-12-07
Novartis’ Pluvicto Continues Winning Streak In Prostate Cancer Indication
2022-12-07
Algernon Wins FDA Orphan Drug Designation For Rare Lung Disease Candidate
2022-12-07
European Commission Continues Fight with Illumina and Orders Grail Acquisition Divestment
2022-12-07
EVENT
2022-12-10
64TH ASH ANNUAL MEETING & EXPOSITION
New Orleans, USA
2022-12-14
BIOHK2022
Hong Kong, China
2022-12-21
Avatar Medicine Forum
Online
2023-01-07
7th Asia Microbiome Conference
Taipei, Taiwan
2023-01-09
JPM Annual Healthcare Meeting 2023
San Francisco, USA
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!